Amgen (AMGN) Tops Q3 EPS by 28c; Raises Outlook

Amgen (NASDAQ: AMGN) reported Q3 EPS of $4.96, $0.28 better than the analyst estimate of $4.68. Revenue for the quarter came in at $6.9 billion versus the consensus estimate of $6.92 billion.

GUIDANCE:

Amgen sees FY2023 EPS of $18.20-$18.80, versus the consensus of $17.31. Amgen sees FY2023 revenue of $28-28.4 billion, versus the consensus of $25.99 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• FTC files amicus brief challenging Amgen's Enbrel patent acquisition
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Amgen (AMGN) PT Raised to $362 at Morgan Stanley